Latest Commercialization News

Prescient Therapeutics has launched a $7 million Share Purchase Plan at a notable discount to fund the next phase of clinical trials for its promising PTX-100 cancer therapy. The capital raise aims to accelerate progress toward regulatory approval and patient access.

Artrya Limited announces a strategic leadership reshuffle with co-founder John Konstantopoulos stepping into the CEO role as the company prepares for its U.S. commercial launch of the Salix® AI-powered platform.

Saturn Metals has reported a new zone of thick, high-grade gold intersections at its Apollo Hill project, significantly enhancing its exploration potential. The newly defined 'Iris Zone' shows promising mineralisation open along strike and down plunge.

Orthocell Limited has posted a record quarterly revenue of A$2.73 million, driven by strong Australian sales of its nerve repair product Remplir™, with US market expansion poised to accelerate in FY26.

Energy World Corporation Ltd plans to convert $440.5 million of debt into shares at a significant premium, reshaping its capital structure and boosting major shareholders’ stakes. Concurrently, the company announces key leadership changes to steer its next growth phase.

Brazilian Critical Minerals Ltd has successfully demonstrated in-situ recovery (ISR) of rare earth elements at its Ema project using an environmentally friendly magnesium sulfate leaching process, marking a pivotal step toward sustainable, low-cost rare earth production.

Adriatic Metals has officially declared commercial production at its Vareš Silver Operation in Bosnia and Herzegovina, overcoming earlier operational hurdles. This milestone sets the stage for steady output and stronger cash flow.

First Graphene Limited has secured two significant orders totaling approximately A$165,000 for its PureGRAPH graphene products, signaling growing market acceptance and supporting its FY25-26 sales outlook.

Green Critical Minerals has released a robust Pre-Feasibility Study for the McIntosh Graphite Project, highlighting significant economic potential and a long mine life. Meanwhile, NH3 Clean Energy advances its flagship WAH2 ammonia project towards key development milestones.

Future Battery Minerals has revealed significant shallow gold intercepts and broad surface anomalies at its Burbanks East Project, with drilling at the nearby Miriam Project scheduled to start in July 2025.

Paradigm Biopharmaceuticals has locked in a $27 million USD convertible note facility to fully fund its pivotal Phase 3 trial for knee osteoarthritis, ensuring operational momentum through key clinical milestones.

Proteomics International, alongside key partners, is investing $6 million to expand the WA Proteomics Facility, aiming to establish a nationally accredited platform for industrial-scale protein biomarker analysis in medicine and agriculture.